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Abstract
Purpose of review Observational studies have shown that serum 25-OH vitamin D [25(OH)D] is inversely associated
with overall cancer risk in many malignancies. We performed a systematic literature review to determine whether
vitamin D deficiency is related to head and neck cancer (HNC) etiology and outcome.
Recent findings The search yielded five prospective studies reporting 25(OH)D levels prior to cancer diagnosis and
their effect on the risk of HNC. Eight studies were cross-sectional or case-control studies, in which 25(OH)D levels
were only measured after cancer diagnosis. Two studies found an inverse association between 25(OH)D level and
HNC risk, while two other prospective cohort studies demonstrated no connection between 25(OH)D and HNC risk.
Several studies reported cancer patients to have significantly lower 25(OH)D levels than controls. Associations
between 25(OH)D and prognosis and mortality were variable.
Summary The link between vitamin D and HNC has so far only been investigated in a few observational, prospective, and case-
control studies. VitaminD deficiencymay bemore common inHNC patients than in the healthy population. There is no evidence
for a causal relationship. Further studies are needed to evaluate whether low 25(OH)D concentrations play a role in the devel-
opment or outcome of HNCs.
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Introduction
The recent GLOBOCAN report on cancer burden worldwide
estimates that there is a steady increase in the incidence of
head and neck cancer (HNC) [1]. Besides the well-known
causative factors such as smoking, heavy drinking, and human
papillomavirus behind this increase, several others have been
suggested but remain inadequately investigated [2]. More re-
search is therefore needed to identify novel preventive and
treatment measures [3].
Recent research has suggested a role for vitamin D in HNC.
Ingested vitamin D undergoes two hydroxylation steps to be-
come the active metabolite. Pre-vitamin D is also synthesized
in the skin from dehydrocholesterol by UV radiation. Vitamin
D is then converted in the liver to 25-hydroxyvitamin-D
(25(OH)D), or calcifediol. This precursor of active vitamin
D undergoes another hydroxylation step in the kidneys to
become the active form of vitamin D, 1alpha-25-
dihydroxyvitamin D (1,25(OH)2D), or calcitriol. Calcitriol is
the hormonal form of vitamin D and functions systemically
via the vitamin D receptor (VDR), present in various tissues
and cells. Vitamin D has long been recognized as having an
important role in the regulation of calcium homeostasis and in
maintaining bone health. Active vitamin D promotes calcium
absorption from the digestive tract and reabsorption in the
kidneys. Calcium is released from the bones through parathy-
roid hormone regulation. In recent decades, however, both
VDRs and 1alpha-hydroxylase have been found in several
other tissues beyond those traditionally associated with vita-
min D metabolism, suggesting a more versatile role in whole
body homeostasis [4••].
Some studies have explored a possible cause and effect
relationship between 25(OH)D levels and disease risk. For
example, a correlation between 25(OH)D levels and myocar-
dial infarction has been found. Vitamin D has also been sug-
gested as a possible treatment for autoimmune diseases due to
its ability to block inflammation mediated by T cells. In addi-
tion, vitamin D derivatives have been successfully used to
treat certain skin diseases such as psoriasis and acne [5, 6].
In mouse and hamster studies, vitamin D has been found to
reduce the growth and development of HNCs [7–9]. In vitro
studies show that the effects are mediated through several
mechanisms. These include inhibiting proliferation and angio-
genesis, as well as potentially reducing metastasizing.
Inhibition of proliferation appears to be based on cell cycle
arrest in the G0/G1 phase [10–12] by vitamin D or its deriv-
atives by activating expression of the cell cycle-regulating
inhibitor proteins p21 and p27 [13–15]. Inhibition of angio-
genesis is suspected to be due to decreased HBp17/FGFBP-1
protein expression caused by 1,25(OH)2D or its derivatives.
This will in turn lower the levels of the angiogenic fibroblast
growth factor-2 (FGF-2) [16, 17]. In one study, 1,25(OH)2D
reduced the production of angiogenic growth factors VEGF
and PDGF in oral cancer cells [12]. An effect on metastatic
potential was revealed in only one study, which found that the
vitamin D analogue MART-10 inhibited head and neck squa-
mous cell carcinoma (HNSCC) cell migration and invasion
into other tissues and reduced epithelial–mesenchymal transi-
tion by inhibiting Snail, Twist, and MMP-9 expression [18].
Observational studies have demonstrated that 25(OH)D
level is inversely associated with overall cancer risk and the
risk of intestinal cancer [19, 20], but not prostate cancer [21].
Based on other cancer studies, low 25(OH)D concentrations
may be associated with a greater risk of HNC. Duffy et al.
noted in preclinical studies that calcitriol enhanced the effect
of certain cytotoxic agents in cancer cells. Vitamin D supple-
mentation increased disease-free survival in patients with
breast cancer or colon cancer. A higher 25(OH)D level was
associated with a better prognosis [22]. These observations
suggest that vitamin D supplementation may have an effect
on treatment or prognosis. However, a recent review on meta-
analyses on observational studies reported that compelling
evidence showing that vitamin D supplementation effectively
improves survival of patients with cancer remains lacking
[23].
In this literature review, we have focused on studies eval-
uating vitamin D as an etiological and prognostic factor for
HNCs. We wanted to better understand the role of vitamin D
in HNC by analyzing epidemiological studies regarding
25(OH)D levels in this patient population. Our hypothesis
was that low 25(OH)D level is a predisposing factor in
HNC. In addition, we searched for studies evaluating the ef-
fect of low 25(OH)D levels on cancer treatment outcomes,
complications, and risk of cancer recurrence.
Materials and Methods
This study followed the 2009 PRISMA criteria (Preferred
Reporting Items for Systematic Reviews and Meta-Analysis)
applied to a systematic review [24].
Inclusion Criteria
The first inclusion criterion was that the selected study had to
include people with HNC. Studies comprising participants
with other cancers were included if separate results were avail-
able for HNC. The inclusion criterion for vitamin D was that
serum 25(OH)D levels were measured. The literature review
was limited to English-language publications. The review in-
cludes studies using the same material with different end-
points. Inclusion criteria did not, however, require certain end-
points from the included studies. The studies needed to have
assessed the connection between 25(OH)D levels and HNC or
compared 25(OH)D levels between HNC patients and a con-
trol population.
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Exclusion Criteria
We excluded from the systematic review studies that focused
on the effect of vitamin D supplements on cancer treatment
and studies which dealt with the connection between vitamin
D and HNC at a cellular level or in animals.
Search Methods
The systematic review was performed using the database sys-
tems of Ovid Medline, PubMed, and Scopus. Initially
searches used several different terms to yield a limited but
nevertheless comprehensive result.
First, we tested the effect of different search terms on
the distribution of results, and based on the test queries
(Appendix 1: searches 1–3, 6–7), we decided for the
Medline search to use the MeSH terms “vitamin D”
and “head and neck neoplasms.” From these, more pre-
cise MeSH terms were included: “squamous cell carci-
noma of head and neck,” “mouth neoplasms,” “laryn-
geal neoplasms,” “nose neoplasms,” and “pharyngeal
neoplasms.” The MeSH term “vitamin D” was extended
to cover all the sub-terms, such as “cholecalciferol,”
“ergocalciferol,” “calcitriol,” and “25-hydroxyvitamin
D2.” In addition, we included search terms outside the
MeSH terms: “head and neck” and “cancer,” “head and
neck carcinoma,” and “vitamin D.”
Based on the practice searches in PubMed (Appendix 1,
searches 4 and 9), we selected the MeSH major topic terms
“head and neck neoplasms.” In addition, the MeSH term “vi-
tamin D” was used in the search, which was extended to
include “ergocalciferols.” For the Scopus search terms, we
selected keywords with the proximity operators “head W/2
neck W/2 cancer” and “vitamin W/2 D.”
The final Medline search was performed on 17th of
February 2020, the final PubMed search on 19th of February
2020, and the Scopus search on 10th of February 2020. For
clarity we decided to only examine studies that measured the
subjects’ 25(OH)D levels.
Data Collection
From the selected studies, we collected information on the
method for measuring vitamin D, sample size, subjects’
cancer, nationality, ethnicity of both the subjects and con-
trol group, and subject endpoints. The reported results
were recorded as an odds ratio (OR), relative risk (RR),
or hazard ratio (HR), if they had been specified. If the
above ratios were not specified, results were reported in
values, for example, the median vitamin D levels or vita-
min D deficiency rate.
Assessment of the Sources of Error
The sources of error of selected studies were assessed using a
model developed by Viswanathan et al., the Item Bank for
Assessing Risk of Bias and Confounding for Observational
Studies of Interventions or Exposures [25].
Results
Selected Studies
We examined a total of 276 studies, and after the inclusion and
exclusion criteria were applied and duplicates removed, 13
studies remained (Fig. 1). In addition to these 13 studies, 13
studies investigated the connection between vitamin D and
HNC, but they had to be excluded as they did not measure
25(OH)D. Details of these studies are summarized in
Appendix 2.
Based on the assessment of source error, we detected a risk
of non-participation bias in five out of the 13 included studies,
when the most unwell or at-risk individuals did not participate
the study [26•, 27, 28, 29•, 30•]. In three of the studies, there
was a risk that this reduction in participation may result in bias
due to small sample size [31–33]. The source of error assess-
ment suggested that in six studies there was a risk of con-
founding bias as they did not sufficiently incorporate con-
founding factors. In their analyses, these studies did not take
into account the seasonal variation in the participants’
25(OH)D levels or sun exposure [32–37]. In six studies, the
subjects’ alcohol consumption was not considered, and five
studies did not consider the subjects’ smoking habits [32–34,
36, 37].
Table 1 summarizes the studies found in the review and the
data collected from them. The search yielded five prospective
studies [26•, 27, 28, 29•, 30•] reporting data on measured
25(OH)D levels prior to cancer diagnosis and the effect of
these levels on the risk of HNC. The other eight studies were
cross-sectional or case-control studies, in which 25(OH)D
levels were only measured after cancer diagnosis.
Five studies focused on Nordic populations, four on
European populations, two on North American populations,
one on an Indian, and one on an Egyptian population
(Table 1).
In three studies, the primary endpoint was overall occur-
rence of cancer. HNC risk was therefore not a specified end-
point, but the studies were included as they provided separate
data regarding HNCs. In four studies, the endpoint was HNC
risk, for three studies it was mortality, and in two studies,
survival time. Two studies had an endpoint related to cancer
treatment outcome, one on mucositis and muscle loss and the
other on risk of recurrence and risk of secondary cancer. In
four studies, the endpoint could not be determined, because
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the only analyses they contained were comparisons of median
measured levels of 25(OH)D or vitamin D deficiency status
between different groups (Table 1).
Cancer Risk
In terms of cancer risk, two studies found an inverse as-
sociation between 25(OH)D level and HNC risk [26•, 27].
In the EPIC cohort study, a case-control study involving
350 HNC patients and individually matched controls,
Fanidi et al. [26•] found that doubling of 25(OH)D plas-
ma levels significantly reduced the cancer risk in the HNC
patients compared with the controls. In addition, Afzal
et al. [27] stated in their Danish prospective cohort study
including 122 HNC patients that a 50% decrease in
25(OH)D plasma levels significantly increased cancer
risk. In contrast, two prospective cohort studies by
Skaaby et al. [28] and Arem et al. [29•] demonstrated
no connection between 25(OH)D and HNC risk.
In several studies, cancer patients were found to have sig-
nificantly lower 25(OH)D levels than controls. Anand et al.
[34] noted the same for oral cancer patients that Mostafa et al.
[35] and Bochen et al. [36] observed for head and neck squa-
mous cell carcinoma patients in general: all these patient
groups had significantly lower 25(OH)D levels as compared
with healthy controls. Orell-Kotikangas et al. [31] demonstrat-
ed in a series of 65 HNSCC patients that vitamin D deficiency
was significantly more prevalent in these patients than in the
Finnish population in general. Similarly, Grimm et al. found
in all 42 oral cancer patients either moderate or severe vitamin
D deficiency [32].
Post-treatment Survival and Mortality
Weinstein et al. [30•] found in a prospective cohort study
comprising 398 male smokers in Finland no connection be-
tween 25(OH)D levels and HNC mortality. Similarly, Meyer
et al. [38] did not find an association between 25(OH)D levels
and mortality in 522 Canadian HNC patients. Fanidi et al.
[26•] found an inverse association between 25(OH)D levels
and mortality in HNC patients; however, when the stage of
cancer was taken into account, the association was significant-
ly weaker.
Both Bochen et al. [36] and Gugatschka et al. [37] found
higher 25(OH)D levels prior to treatment to be associated with
longer post-treatment survival. In the latter study, the authors
also observed an association with longer disease-free survival.
Bochen et al. found that higher 25(OH)D levels were associ-
ated with higher peri-tumoral immune cell infiltration [36].
Cancer Complications and Risk of Recurrence
A study on complications in cancer treatment found that in
Canadian HNC patients, lower 25(OH)D levels were associ-
ated with more serious mucositis and lower muscle mass [33].
Meyer et al. did not find a relationship between 25(OH)D
levels and risk of HNC recurrence or the occurrence of sec-
ondary cancer [38].
Fig. 1 Flow chart for the search
(HNC = head and neck cancer)
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Discussion
Systematic reviews of the relationship between vitamin D and
HNC have not been conducted previously. The present review
revealed that the results from the studies were varying, show-
ing evidence of both for and against an association between
the risk of HNC and level of 25(OH)D. However, in all five
studies that compared 25(OH)D levels between HNC patients
and healthy individuals, HNC patients were found to have
much lower levels of vitamin D. In two out of three studies,
25(OH)D level was not observed to have an effect on mortal-
ity. However, higher 25(OH)D levels were observed to have a
protective effect on survival.
The studies show that vitamin D deficiency may be more
common in HNC patients than in the healthy population.
There is no evidence for a proven causal relationship.
Cancer patients’ lower 25(OH)D levels could be partially ex-
plained by the eating and swallowing difficulties caused by
the cancer and its treatment. As a result, dietary intake of
vitamin D may be reduced.
When vitamin D was observed to have an inverse associa-
tion with HNC risk, this was then also correlated with
smoking. Afzal et al. focused on tobacco-related cancer risk
[27], and Fanidi et al. found an association only in smokers or
ex-smokers [26•]. Afzal et al. found 25(OH)D levels to be
associated only with smoking-related cancers, such as lung,
head and neck, bladder, kidney, liver, and esophageal cancers,
but not with other cancers [27]. The protective effect of high
vitamin Dmight only be associated with HNC cases related to
smoking.
We observed in the included studies several potential
sources of bias as some patient groups did not participate
the study, the sample size in the series was small, or the con-
founding factors were not sufficiently incorporated. Further,
in a significant number of studies, the main circulating vitamin
D metabolite 25(OH)D was not measured, and the studies
failed to fulfill our inclusion criteria.
Meta-analyses and randomized controlled trials (RCT) on
the effect of vitamin D on cancer risk in general have so far
yielded contradictory results. In a RCT of postmenopausal
women, vitamin D + calcium supplement decreased their all-
cancer risk [39]. However, another RCT found no association
between vitamin D and invasive cancer risk [40]. Based on
meta-analyses, however, vitamin D supplementation does ap-
pear to be associated with lower total cancer mortality [41,
42]. Keum et al. found that it did not have an effect on total
cancer incidence [42]. More research is needed, with suffi-
ciently long follow-up and assessment of the subject’s base-
line 25(OH)D levels.
The role of vitamin D in HNCmanagement has been large-
ly ignored. Studies to date have not identified a clear clinical
effect on vitamin D treatment outcome. The best evidence for
the benefits of vitamin D in cancer treatment would be
provided by a RCT. However, such studies have not been
conducted for HNCs. They would require long follow-up pe-
riods, which affect subject compliance. Also, there is uncer-
tainty as to the optimal dose of vitamin D for cancer treatment
or prevention.
The existing studies regarding administration of vitamin D
have, for example, observed a stimulating effect on the im-
mune system of HNC patients. Walsh et al. observed that a
1,25(OH)2D supplement given prior to surgery increased CD4
and CD8 cell levels for 3 weeks and increased CD69 expres-
sion, suggesting T cell activation. They also found
1,25(OH)2D treatment to be effective in prolonging the time
to recurrence of cancer. The results were not statistically sig-
nificant due to the small sample size [43]. Lathers et al.
showed that 25(OH)D supplements improved the immune
response of HNC patients by temporarily reducing the number
of CD34-positive cells and increasing the number of IL-12
and IFN-γ-neurotransmitters [44]. Walker et al. observed that
giving 1,25(OH)2D treatment prior to surgery increases the
plasma levels of both type 1 and type 2 T helper cell system
mediators. Giving 1,25(OH)2D supplement also increased the
levels of the tumorigenic and angiogenic mediators IL-8 and
VEGF in plasma, but not in cancerous tissue [45].
The strength of our review is a comprehensive systematic
literature search performed according to strict criteria. Results
which both strengthen and weaken the association were ob-
served, so the risk of reporting bias is low.
Conclusions
This review revealed that the link between vitamin D and
HNCs has so far only been investigated in observational
and case-control studies. Based on current knowledge, it is
not possible to definitively deduce a causal connection be-
tween HNCs and vitamin D. Our results suggest an inverse
relationship between the risk of HNC and 25(OH)D level.
Further, there may be a direct relationship between
25(OH)D levels and both overall and disease-specific
HNC survival. However, there has not been a single RCT
on the efficacy of vitamin D supplements as a preventive
measure against HNC occurrence or on treatment outcome.
Such RCTs are needed to provide more data and to guide in
vitamin D supplementation recommendations for patients
with HNC.
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